Longevity World Forum confirms Valencia as its venue in 2019

After the success of its first edition at the end of 2018, it was announced during the closing ceremony of the first Longevity World Forum that a second edition would be held. The organisers of this international congress, a pioneering event in Europe on human longevity, have now confirmed this, specifying that it will take place on 13 and 14 November 2019 at the Palacio de Congresos (Conference Centre) of Valencia, a city that will thus be consolidated as a scientific capital on a global scale.

This decision is the result of the good context currently offered by Valencia, where the academic and scientific ambience, accompanied by innovation and research, present a notable development. Added to this is a growing biotechnology and biomedicine cluster comprising numerous companies and organisations with national and international projection. With all this in mind, the organisers of the Longevity World Forum have once again opted for the city on the river Turia ahead of bids from other European cities to host the event.

Therefore, for the second year running, Valencia will serve as a meeting point for the world scientific community and representatives from academia and industry from different countries, whose work is intimately related to increasing life expectancy and healthy aging. Thus, human longevity will once again be examined from different perspectives, generating multidisciplinary knowledge and showing the latest advances in this field. In short, the organisers of the Longevity World Forum aspire to improve on the good results of its first edition, which boasted over 400 attendees and a programme that included more than 20 first-class speakers. For example, this was the case of Aubrey de Grey, the famous biogerontologist and founder of the American organisation SENS Research Foundation; Ángela Nieto, director of the Developmental Neurobiology Unit of the Neuroscience Institute of Alicante UMH-CSIC; María Blasco, director of the prestigious National Cancer Research Centre (CNIO); José Viña and Federico Pallardó, professors of physiology at the Universitat de València; Lissette Otero, chief medical officer and laboratory director of Life Length; Maria Chatzou, CEO of Lifebit; Manuel Pérez Alonso, professor of genetics at the UV; and Manuel Corpas, founder and CEO of Cambridge Precision Medicine; among other relevant voices.

Valencia: Longevity World Forum. Daniel Duart/Talentum.

The scientific community shared a “tsunami of knowledge” on healthy ageing at the Longevity World Forum

“We are an increasingly ageing society and this is a challenge.” That is how Manuel Pérez Alonso, Professor of Genetics at the University of Valencia, started his closing speech at the Longevity World Forum, the first conference in Europe focused on life expectancy and life improvement. We know for a fact that human longevity is gradually increasing and this results in serious consequences in many areas. That is why a world forum for reflection is needed.

The Longevity World Forum responds to this need. Its first edition has been held in the Valencia Conference Centre and it has brought together over 400 participants, who have had the opportunity to learn more about longevity from the perspective of world leaders of the scientific community in fields such as genomics, nutrition, precision medicine and biotechnology. They have shared their knowledge, informed about the latest achievements and analysed new challenges.

“Ageing cannot be treated directly. However, the illnesses that result from this natural process can be treated”, explained María Blasco, Head of the prestigious Spanish National Cancer Research Centre (CNIO), who was one of the speakers in the conference together with other professionals such as Ángela Nieto, head of the Developmental Neurobiology Unit of the UMH-CSIC Neuroscience Institute located in Alicante, who has just received the ASEICA Cancer Research Award 2018; or the renowned Aubrey de Grey, founder of SENS Research Foundation, who was the last speaker and argued that combating ageing as a medical condition will be possible in the near future.

In total, over 20 people were part of a first-rate panel of speakers that combined perspectives from the scientific, academic and professional communities in order to “discover the mechanisms that affect ageing, develop strategies to slow it down and treat age-related illnesses better”, as Manuel Pérez Alonso said in his closing speech. It was also stated that “the future brings an integrative multidisciplinary medicine” based on genomic information and applying artificial intelligence, as well as the fact that a “recipe for a healthy later life” would involve “a responsible diet, physical exercise adapted to each person’s situation and keeping alive social relationships”.

The organizers of Longevity World Forum have expressed their satisfaction since the event was well-received and they achieved the goal of “conveying a tsunami of knowledge” for the benefit of the whole society. Due to its success, the second edition of this event has been confirmed. It will take place in November 2019 and it is expected to become an annual international event.

Aubrey de Grey Longevity

The debate over precision medicine and biotechnology puts the final touch on the first edition of the Longevity World Forum

On the second and final day of the Longevity World Forum, the conference turned its focus towards two disciplines which are fundamental to guarantee a longer and better life expectancy: precision medicine and biotechnology. Each one of these was the focus of a session which, once again, heard from leading voices not only from within the scientific community but also from industry thus providing a more holistic vision of human longevity.

In particular, Manuel Corpas, CEO and founder of Cambridge Precision Medicine, started the day by demonstrating how complete genomic sequencing is a key tool for clinical practice that aims at prolonging human life and health. The testimonial of Jorge Cortell, CEO of Kanteron Systems, added to this as he explained how his start-up integrates data from the image into the medical workflow to make it more accurate and personalised.

Ana Sabater, Associate Director of Eugenomic, continued in this line, emphasising pharmogenetics and its value to making prescribing safer, which translates into a more efficient medical industry. In addition, Arancha Galán, Deputy Director of the IVI in vitro fertilization laboratory, dismantled the widespread idea of eternal youth and cautioned that the need to consider mechanisms to preserve fertility is ever more important now that life expectancy is longer.

All of them together with Pablo Marín, Director of Bioinformatics of Kanteron Systems; Juan Sabater, Head of Eugenomic; Elisa Tarazona, Operations Manager of Ribera Salud; and Gonçal Lloveras, Managing Director of Clínica Diagonal in Barcelona, also participated in different round tables which covered, on the one hand, the potential for Big Data in health management and, on the other hand, the role of clinics, laboratories and hospitals under the new medical paradigm.

The fourth session, which took place throughout the day, benefited from the contributions of Tom Stubbs and Attila Csordas, founder and CEO of Chronomics and Age Curve Limited, respectively. They showed how their startups offer services which already allow information gathering from genetics or biomarkers with the aim of developing a preventive medical system.

In between these two, it was the eagerly-awaited Aubrey de Grey’s turn. The renowned biogerontologist founder of SENS Research Foundation argued that ageing will be treated like a mere health problem in the near future. That is to say, ageing is not like an infection that can be eradicated from the human body but it will be like other illnesses that result from the “accumulation of harm” on the human body.

Lissette Otero, CMO and Laboratory Director of LifeLength, intervened last giving a breakdown of the different variables associated with telomeres, age and cancer. Lastly, Ángel Alberich, founder and CEO of Quibim, illustrated the current medical applications that artificial intelligence already has and the advantages it offers in terms of guaranteeing healthy longevity.

Manuel Pérez Alonso, Professor of Genetics at the University of Valencia and member of the conference scientific and organizing committees, summed up the key conclusions in the closing speech of the Longevity World Forum and confirmed that a second annual conference will take place next year since the first edition has been very well-received.

The scientific community proposes a different approach to ageing at the Longevity World Forum

It may seem paradoxical but embryonic development is not dissimilar to ageing, acknowledged Ángela Nieto at the Longevity World Forum. The head of the Developmental Neurobiology Unit of the UMH-CSIC Neuroscience Institute located in Alicante, who has just received the ASEICA for Best Investigative Career, was one of the speakers in the conference’s first day. There she explained the existence of “promising therapeutic targets” for organ degeneration which would mean longer and better life expectancy.

In addition, María Blasco, Head of the Spanish National Cancer Research Centre and also a speaker in this conference, emphasised the study of telomeres and telomerase due to their proven direct effect on the development of particular pathologies associated to ageing. “Ageing cannot be treated directly. However, the illnesses that result from this natural process can be treated”, she explained.

José Viña y Federico Pallardó, both Professors of Physiology at the University of Valencia (UV), were also some of the key speakers in the first day of the Longevity World Forum. In particular, Federico Pallardó argued that ageing is a physiological progress which can be delayed thanks to epigenetic mechanisms. Meanwhile, Manuel Viña defended the idea that nutrition and physical exercise can be considered “new medications” with their influence on age-related frailty being a key piece of evidence in this argument.

The presentations of Mercedes Aguirre, head of laboratories Nua Biological Innovations, and Mari Carmen Gómez, who is part of the Physiology Department of the University of Valencia, followed in this vein, using examples such as Alzheimer’s disease to prove the importance of diet and physical activity in achieving healthy ageing.

Therefore, the Longevity World Forum is achieving the target set upon its creation; serve as a world forum to exchange knowledge on increased life expectancy and life quality improvement from a purely scientific perspective. Tomorrow the conference’s second and final day will be seen out with the highlight being the intervention of Aubrey de Grey, the renowned biogerontologist founder of SENS Research Foundation. Alongside other professionals, he will further develop speciality subjects like precision medicine and biotechnology.

Research for a longer and better life expectancy focuses on Valencia

The Longevity World Forum is already a reality: the first conference in Europe on precision medicine and genomics started with an opening session in the Valencia Conference Centre where nearly 400 people gathered together. “It’s a risky bet but one which is necessary to enjoy a better quality of life. Doing it from a starting point of scientific knowledge means greater safety”, stated Maite Girau, head of the local Sports and Health, who attended the session as a representative of the Valencia City Council.

Now world leaders in the scientific community will present their ideas and participate in round tables with the objective of creating a world forum on life expectancy and life quality improvement. Leading figures such as Aubrey de Grey, the renowned founder of SENS Research Foundation or Ángela Nieto, head of the Developmental Neurobiology Unit of the UMH-CSIC Neuroscience Institute located in Alicante, who has just received the ASEICA Cancer Research Award 2018.

In total, over 20 professionals will take part in this unprecedented exchange of knowledge that will help Valencia become one of the scientific capitals of the world. José Viña and Federico Pallardó, Professors of Physiology at the University of Valencia, will also attend the conference; as well as María Blasco Marhuenda, head of the Spanish National Cancer Research Centre (CNIO); Manuel Pérez Alonso, Professor of Genetics at the University of Valencia; Manuel Corpas, CEO and founder of Cambridge Precision Medicine; Lissette Otero, Chief Medical Officer and Laboratory Director in Life Length; and Maria Chatzou, CEO of Lifebit, among others.

Subjects like epigenetics, nutrition, “4P” medicine (predictive, preventative, personalised and participative), pharmacology and biotechnology will become the focus of scientific debate about human longevity thanks to a packed programme which includes not only perspectives from healthcare and academia but also from industry. “The idea is to bring an interdisciplinary perspective and involve all of society. Moreover, I hope the conclusions reach administrations because it is vital that, from the public policy-making standpoint, we take these advances into account”, Maite Girau concluded.

Aubrey de Grey Longevity World Forum

Aubrey de Grey announces that age-reversing medication will be a reality in five years from now

The researcher Aubrey de Grey is well known for his strong advocacy that an indefinite life expectancy is possible. He will present his ideas on the 7th and 8th of November in Valencia where the first edition of the Longevity World Forum will take place. This meeting on longevity, genomics and precision is the first of its kind in the world. In addition, the biomedical gerontologist will prove that we are closer to achieving indefinite longevity than we think. “The next key step will take place when results in labs with mice are sufficiently impressive so that people start realising that medicines to keep us young will actually come soon. I would dare to say that in just five years from now.”, he says.

Aubrey de Grey also believes that treatments to conquer death will be accessible to everybody.  As he said, “They will be absolutely available to all those old enough to need them. This will be economically feasible because the elderly population will keep active instead of becoming an expense. In addition, these medicines will be developed, at least one decade before they are perfected, hence both governments and industries will have time to implement the necessary changes to ensure that there are no delays in providing universal access.

Reservations have been expressed about Aubrey de Grey’s ideas both from the scientific and social point of view, as well as due to its impact on the sustainability of the planet. However, he counters criticism with his conviction that the consequences of human longevity are not worrying. “It is only possible to think that this would be an issue if all the technologies that are being developed even before rejuvenation, which will reduce pollution, are ignored. Once we have ubiquitous renewable energy, artificial meat, and desalinization, all very cheap, more people will be able to inhabit the Earth with a lower environmental impact than nowadays“, he explains.

Aubrey de Grey’s perspective comes from his concept of the human body, which he conceives as some sort of machine. “We need a comprehensive preventive maintenance strategy. This way, we will get rid of the harm that our own functioning produces before it is too much and we become ill. The only problem is that we still have not developed all the technology that allows us to do so, but we are close!”, he says.

Whether you agree or not with him, the truth is that he captures everybody’s attention. The Longevity World Forum is the first European conference on longevity, genomics and precision medicine where Audrey de Grey will participate. The conference will be held in the Valencia Conference Centre on the 7th and 8th of November with the participation of world leaders of the scientific community such as María Blasco, head of the Spanish National Cancer Research Centre; Ángela Nieto, head of the Developmental Neurobiology Unit of the UMH-CSIC Neuroscience Institute located in Alicante; Manuel Corpas, CEO and founder of Cambridge Precision Medicine; Lissette Otero, Chief Medical Officer and Laboratory Director in Life Length; and Maria Chatzou, CEO of Lifebit, among others. Tickets are still available on the official website www.longevityworldforum.com.

Calico-Longevity-World-Forum-Valencia-2018

Calico, Google’s biotech company, joins the Longevity World Forum

The pioneering nature and professional approach of the Longevity World Forum is attracting the attention of different actors involved in the fields of longevity, genomics and precision medicine. Less than two months away from the first edition, the event has gained the support of Calico, a biotech company that, under the umbrella of Google, works in the research and development of this field.

The organizers of the #Longevity18 have stated “it is great news that a company such as Calico joins the Longevity World Forum for several reasons. It reflects the need to hold an event such as this one which addresses an issue that affects the society as a whole. In addition, as a result, everyone interested in scientific and medical development will have their eyes on Spain in general and on Valencia in particular”.

Ever since Calico was established in 2013, the company has focused on combating ageing and associated diseases. In order to do so, it has a multidisciplinary team of scientists from the fields of medicine, genetics and molecular biology, among others. Calico aims at providing the environment to support innovation and improve human health, as the company explains.

El Longevity World Forum has been conceived as a project that serves this mission, that is, an event that becomes a meeting point to pool knowledge and create synergies to extend life expectancy and improve life quality. Hence, world leaders of the scientific community will gather together in the Valencia Conference Centre on the 7th and 8th of November.

Among others, the following renowned professionals will take part in Longevity World Forum: Aubrey de Grey, biomedical gerontologist and founder of SENS Research Foundation; María Blasco Marhuenda, head of the Spanish National Cancer Research Centre; José Viña and Federico Pallardó, Professors of Physiology at the University of Valencia; Ángela Nieto, head of the Developmental Neurobiology Unit of the UMH-CSIC Neuroscience Institute located in Alicante; Manuel Pérez Alonso, Professor of Genetics at the University of Valencia; Manuel Corpas, CEO and founder of Cambridge Precision Medicine; Lissette Otero, Chief Medical Officer and Laboratory Director in Life Length; and Maria Chatzou, CEO of Lifebit.

#Longevity18 is an initiative promoted by the consulting firm Talentum Group in collaboration with the agency Medigene Press, which publishes the journal Genética Médica News, as well as the international company Cambridge Precision Medicine. Tickets are limited but they are still available on the official website www.longevityworldforum.com. Those interested in attending the event who can provide evidence that they belong to an academic institution or a professional association will receive special discounts.

Longevity 2018 Participantes

Valencia is getting ready to welcome world leaders of the scientific community to the Longevity World Forum

The Longevity World Forum will be held soon in the Conference Centre on the 7th and 8th of November. The city of Valencia will become a meeting point for the scientific community, both at a national and international level, since this is the first gathering in Europe that will address topics of current interest such as longevity, genomics and precision medicine.

#Longevity18 is an initiative promoted by the consulting firm from Valencia Talentum Group; the company Medigene Press, which publishes the journal Genética Médica News; and the international company Cambridge Precision Medicine. The organizing partners explain that the purpose of this event is to create a meeting point for all the actors involved in the study of life expectancy and improvement of the quality of life. Therefore, the Longevity World Forum is open to all students, scientific researchers, and professionals from the healthcare, pharmacy and biotechnology industry. The conference agenda has been designed to pool all the existing knowledge on the latest achievements and to create synergies that allow the scientific community to face the numerous challenges of the immediate future.

The interest generated by the Longevity World Forum is not surprising given its panel of high-level participants. Among others, the following renowned professionals will take part in Longevity World Forum: Aubrey de Grey, biomedical gerontologist and founder of SENS Research Foundation; María Blasco Marhuenda, head of the Spanish National Cancer Research Centre; José Viña and Federico Pallardó, Professors of Physiology at the University of Valencia; Ángela Nieto, head of the Developmental Neurobiology Unit of the UMH-CSIC Neuroscience Institute located in Alicante; Manuel Pérez Alonso, Professor of Genetics at the University of Valencia; Manuel Corpas, CEO and founder of Cambridge Precision Medicine; Lissette Otero, Chief Medical Officer and Laboratory Director in Life Length; and Maria Chatzou, CEO of Lifebit.

Tickets for the first edition of Longevity World Forum are limited and available on the official website: www.longevityworldforum.com. Those interested in attending the event who can provide evidence that they belong to an academic institution or a professional association will receive special discounts.

Longevity World Forum Valencia Joan Ribo

Longevity World Forum chooses Valencia to host its first edition

The Longevity World Forum provides an opportunity for the scientific community to share and develop advances in human longevity. This is the aim of the Longevity World Forum, a new global meeting, which is the first of its kind in Europe and will take place on the 7th and 8th of November in Valencia and will gather eminent personalities in the field, both from Spain and abroad, who will share their knowledge from the perspective of scholars, researchers and professionals.

This exchange of ideas and synergies will take place at the Valencia Conference Centre, which has been the venue chosen to host the first edition of Longevity World Forum next autumn. This project has been organized by the consulting firm Talentum Group in collaboration with the agency Medigene Press, which publishes the journal Genética Médica News, as well as the international company Cambridge Precision Medicine. Representatives of the aforementioned entities have already met with the Mayor Joan Ribó, who has confirmed the support of the local government to this initiative.

Among others, the following renowned professionals will take part in the first edition of Longevity World Forum: José Viña and Federico Pallardó, both Professors of Physiology at the University of Valencia; María Blasco Marhuenda, head of the Spanish National Cancer Research Centre; Manuel Corpas, CEO and founder of Cambridge Precision Medicine; Ángela Nieto, head of the Developmental Neurobiology Unit of the UMH-CSIC Neuroscience Institute located in Alicante; Tom Stubbs, CEO of Chronomics; Aubrey de Grey, biomedical gerontologist and founder of SENS Research Foundation; and Christoph Lippert, Group Leader at the Max Delbrück Center for Molecular Medicine in Berlin.

Longevity World Forum aims at becoming a meeting point for scientists and other international actors involved in research and the development of approaches to increase life expectancy and improve life quality. The world forum will last two days and its programme will address fields such as genomics, precision medicine, nutrition and physical activity applied to human longevity, which is a matter people are growing increasingly concerned about.

Longevity18 date location

Longevity World Forum is the new international meeting in Valencia that will promote knowledge on human longevity

An opportunity for the scientific community to share and develop advances in human longevity. This is the aim of Longevity World Forum, a new global meeting, which is the first of its kind in Europe and will take place on the 7th and 8th of November in Valencia gathering eminent personalities in the field of human longevity both from Spain and abroad.

Among others, the following renowned professionals will take part in Longevity World Forum: Aubrey de Grey, biomedical gerontologist at SENS Research Foundation; Christoph Lippert, data science specialist at Human Longevity; María Blasco Marhuenda, head of the Spanish National Cancer Research Centre; Manuel Corpas, CEO and founder of Cambridge Precision Medicine; and Santiago Grisolía, biochemist, Prince of Asturias Award winner and chairman of the Scientific Committee of the Human Genome Project for UNESCO.

Longevity World Forum aims at becoming a meeting point for scientists and other international actors involved in research and the development of approaches for increased life expectancy and improved life quality. The world forum will last two days and its programme will address fields such as genomics, biotechnology and nutrition applied to human longevity, which is a matter people are growing increasingly concerned about.

This exchange of ideas and synergies will take place at Hotel Las Arenas Balneario Resort next autumn. The hotel is located in Valencia, the city chosen to host the first edition of Longevity World Forum and to be the permanent venue of the event. Longevity World Forum is a project organized by the consulting firm Talentum Group in collaboration with the journal Genética Médica News and the company Cambridge Precision Medicine.

The tickets for the first edition of Longevity World Forum are limited and available on the official website: www.longevityworldforum.com.